Comparison · NCT02401048-sae
Phase 1b/2: Follicular Lymphoma Expansion Cohort: vs Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort:: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase 1b/2: Follicular Lymphoma Expansion Cohort: vs Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort:: serious adverse events. Trial comparisons, record NCT02401048-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02401048-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.37 | 0.215 | 0.558 | wilson | |
| Risk in group 2 | 0.676 | 0.508 | 0.809 | wilson | |
| Risk difference, group 1 minus group 2 | -0.306 | -0.51 | -0.0544 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.548 | 0.318 | 0.943 | log | |
| Odds ratio, group 1 over group 2 | 0.281 | 0.0973 | 0.813 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Phase 1b/2: Follicular Lymphoma Expansion Cohort: than on Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort: | 3.27 | 1.96 | 18.4 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase 1b/2: Follicular Lymphoma Expansion Cohort: | All subjects who received at least one dose of study treatment. | 10 | 27 | EG000 |
| Group 2 | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort: | All subjects who received at least one dose of study treatment. | 23 | 34 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All AEs, whether serious or non-serious, are documented in the source documents from the time the signed and dated ICF is obtained until 30 days following the last dose of ibrutinib and 90 days following the last dose of MEDI4736.
Source ClinicalTrials.gov
Trial
- Title
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- NCT number
- NCT02401048
- Phases
- PHASE1, PHASE2
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
- Interventions
- Ibrutinib, MEDI4736
- Lead sponsor
- Pharmacyclics LLC.
- Results first posted
- 2019-06-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02401048?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02401048-sae